Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Copyright policy )Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Key Points The novel IFNα-2b, ropeginterferon alfa-2b, administered once every 2 weeks has low toxicity and induces high and sustained response rates in polycythemia vera patients. Ropeginterferon alfa-2b induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden.
- Labor für Immunologische und Molekulare Krebsforschung Austria
- Innsbruck Medical University Austria
- Wiener Krankenanstaltenverbund Austria
- Medical University of Vienna Austria
- Austrian Academy of Sciences Austria
Adult, Aged, 80 and over, Male, Maximum Tolerated Dose, Remission Induction, Interferon-alpha, Interferon alpha-2, Middle Aged, Prognosis, Recombinant Proteins, Polyethylene Glycols, Survival Rate, Humans, Female, Polycythemia Vera, Aged, Follow-Up Studies, Half-Life, Neoplasm Staging
Adult, Aged, 80 and over, Male, Maximum Tolerated Dose, Remission Induction, Interferon-alpha, Interferon alpha-2, Middle Aged, Prognosis, Recombinant Proteins, Polyethylene Glycols, Survival Rate, Humans, Female, Polycythemia Vera, Aged, Follow-Up Studies, Half-Life, Neoplasm Staging
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).161 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!